<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36878316</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6787</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Dermatology</Title><ISOAbbreviation>J Am Acad Dermatol</ISOAbbreviation></Journal><ArticleTitle>Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>173</EndPage><MedlinePgn>171-173</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaad.2023.02.044</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0190-9622(23)00354-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chasset</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Service de Dermatologie et Allergologie, H&#xf4;pital Tenon, INSERM U-1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris) Paris, France. Electronic address: francois.chasset@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaume</LastName><ForeName>L&#xe9;a</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Service de Dermatologie et Allergologie, H&#xf4;pital Tenon, INSERM U-1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris) Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathian</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Groupement Hospitalier Piti&#xe9; Salp&#xea;tri&#xe8;re, Centre National de R&#xe9;f&#xe9;rence du Lupus Syst&#xe9;mique, du syndrome des antiphospholipides et autres maladies auto-immunes, Service de M&#xe9;decine Interne 2, Institut E3M, CIMI-Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abisror</LastName><ForeName>No&#xe9;mie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Service de Medecine Interne, H&#xf4;pital Saint-Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutheil</LastName><ForeName>Am&#xe9;lie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Service de Dermatologie et Allergologie, H&#xf4;pital Tenon, INSERM U-1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris) Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbaud</LastName><ForeName>Annick</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Service de Dermatologie et Allergologie, H&#xf4;pital Tenon, INSERM U-1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris) Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kottler</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service de dermatologie et v&#xe9;n&#xe9;rologie, CHU de Caen, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girard</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de dermatologie et v&#xe9;n&#xe9;rologie, CHU de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jousse-Joulin</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de rhumatologie, CHU de Brest, Universit&#xe9; de Brest, Inserm, LBAI, UMR1227, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tauber</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de dermatologie, CHU de Toulouse, Universit&#xe9; Paul Sabatier Toulouse III, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livideanu</LastName><ForeName>Cristina Bulai</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Service de dermatologie, CHU de Toulouse, Universit&#xe9; Paul Sabatier Toulouse III, Toulouse, France; Infinity, Institut Toulousain des Maladies Infectieuses et Inflammatoires, CNRS, Universit&#xe9; Paul Sabatier Toulouse III, Inserm, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avettand-Fenoel</LastName><ForeName>V&#xe9;ronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, Facult&#xe9; de m&#xe9;decine, Institut Cochin-CNRS 8104/INSERM U1016 AP-HP, Service de Virologie, H&#xf4;pital Cochin, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lhote</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Groupement Hospitalier Piti&#xe9; Salp&#xea;tri&#xe8;re, Centre National de R&#xe9;f&#xe9;rence du Lupus Syst&#xe9;mique, du syndrome des antiphospholipides et autres maladies auto-immunes, Service de M&#xe9;decine Interne 2, Institut E3M, CIMI-Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pha</LastName><ForeName>Micheline</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Groupement Hospitalier Piti&#xe9; Salp&#xea;tri&#xe8;re, Centre National de R&#xe9;f&#xe9;rence du Lupus Syst&#xe9;mique, du syndrome des antiphospholipides et autres maladies auto-immunes, Service de M&#xe9;decine Interne 2, Institut E3M, CIMI-Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amoura</LastName><ForeName>Zahir</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Facult&#xe9; de m&#xe9;decine, AP-HP, Groupement Hospitalier Piti&#xe9; Salp&#xea;tri&#xe8;re, Centre National de R&#xe9;f&#xe9;rence du Lupus Syst&#xe9;mique, du syndrome des antiphospholipides et autres maladies auto-immunes, Service de M&#xe9;decine Interne 2, Institut E3M, CIMI-Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EMSED (Etude des maladies syst&#xe9;miques en dermatologie) study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Dermatol</MedlineTA><NlmUniqueID>7907132</NlmUniqueID><ISSNLinking>0190-9622</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>38RL9AE51Q</RegistryNumber><NameOfSubstance UI="C582345">anifrolumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anifrolumab</Keyword><Keyword MajorTopicYN="N">belimumab</Keyword><Keyword MajorTopicYN="N">cutaneous lupus erythematosus</Keyword><Keyword MajorTopicYN="N">refractory</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Conflicts of interest Dr Chasset received grant/research support from AstraZeneca; participated in an advisory board related to lupus for AstraZeneca, GSK, Celgene, and Principabio; and received speaking fees and honoraria from AstraZeneca and GSK. Dr Mathian has received grant/research support from Sobi; participated in advisory board related to lupus for AstraZeneca; received payment for expert testimony for GSK; received support for attending meetings and/or travel from AstraZeneca and GSK; and received consulting fees, speaking fees, and honoraria from AstraZeneca, GSK, Otsuka, and Novartis. Dr Livideanu received speaking fee and honoraria from Blueprint Medicine, Lilly, and UCB and participated in advisory board for AbbVie, Boehringer Ingelheim, Blueprint Medicine, and UCB. Dr Avettand-Fenoel received grant/research support and speaking fees from Gilead and ViiV Healthcare. Dr Amoura has received grant/research support from GSK, AstraZeneca, Roche, Novartis, and Amgen; participated in advisory board related to lupus for GSK, AstraZeneca, Kezar, Amgen, and Otsuka; and received consulting fees, speaking fees, and honoraria from AstraZeneca and GSK. Drs Jaume, Abisror, Dutheil, Barbaud, Kottler, Girard, Jousse-Joulin, Tauber, Lhote, and Pha have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>6</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36878316</ArticleId><ArticleId IdType="doi">10.1016/j.jaad.2023.02.044</ArticleId><ArticleId IdType="pii">S0190-9622(23)00354-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>